MedLife ended the first nine months of the year with a 12% increase compared to last year. The company is growing sustainably on an organic basis, by 11%, and is seeing robust demand for its services despite a less favorable macroeconomic environment

- *In the first nine months of 2026, MedLife reported pro forma consolidated revenue of 2.64 billion lei, up approximately 12% compared to the same period last year. 11% of this growth was organic.*
- *Part of this growth was driven by the development of a new digital patient experience through the new iMed app, as well as by the launch—a first in Romania—of genomics, microbiomics, and pharmacogenetics services. iMed, the new platform within the MedLife app, brings together medical, genetic, biometric, and lifestyle data into a single ecosystem.*
- *Clinics and hospitals are the main drivers of growth during this period, showing robust performance over the nine-month period, followed by laboratories and the corporate division.*
- *The Group is preparing for a new phase of growth, aimed at strengthening its position in the local market through small and medium-sized acquisitions in the health, beauty, and wellness sectors, as well as gradually exploring opportunities for regional expansion, with a focus on Central and Southeastern Europe.*

Bucharest, 20 November 2026: MedLife, the leader in Romania's healthcare services market, announces its financial results for the first nine months of 2026, reporting pro-forma consolidated revenue of 2.64 billion lei, up approximately 12% compared to the same period last year. In terms of operating profitability, pro-forma EBITDA reached 398.7 million lei, corresponding to a margin of 16.7% of net sales.

These results confirm the resilience of the business model and reflect the contribution of the Group's main business lines to the medical ecosystem it has developed, which is capable of covering the entire medical journey—from personalized prevention and diagnosis to complex treatments and monitoring—complemented by related services, including those in the wellness sector.

The clinic network contributed nearly 39% of revenue, supported by approximately 4 million visits, while the hospital segment accounted for about 27% of the business. The laboratories, in turn, made significant contributions, accounting for approximately 11% of revenue, with nearly 9 million tests processed in the first nine months of 2026.

"*The first nine months of the year confirm the demand and MedLife's ability to continue growing organically, even in an economic environment characterized by caution and cost pressures. Growth through acquisitions was lower, primarily due to the desire to maintain a prudent level of debt. However, it is possible that we will resume the growth rates of previous years—20%—by doubling our current organic efforts with acquisitions. Over the past 15 years, MedLife has proven its ability to make acquisitions and integrate businesses, and we are confident that we can resume this growth, for which we have both the experience and an enviable track record*.

Beyond financial performance, I believe that one of the most important things we are building right now is the next generation of healthcare services. According to our data, MedLife is the only healthcare network in Romania—and likely in Europe—that brings together, within its own iMed app, data from the patient's medical record, genetic and biometric data, personal and family medical history, as well as relevant lifestyle information—and we will soon be integrating data on the microbiome and pharmacogenetics as well. This is a huge step for us and likely for personalized medicine in general," **said Mihai Marcu, CEO and Chairman of the Board of the MedLife Group.**

What the Digital Transformation of the Medical Experience Will Look Like Through the New iMed Interface

Beyond ongoing investments in expanding medical infrastructure and facilitating access to state-of-the-art services and technologies, accelerating digital transformation and advancing personalized medicine remain two of the MedLife Group's main strategic priorities.

An important step in this direction was the launch of iMed, a digital platform within the MedLife app that offers users an integrated view of their own health and helps them understand why routine checkups matter and how they can make taking care of their health a daily habit. In fact, between May and October 2026, organic downloads of the MedLife app increased by 40%, double the rate from the same period last year. In this context, MedLife representatives aim to double the number of accounts on the app by mid-2027. This goal involves attracting, over the next few months, a number of new users comparable to the total accumulated in nearly six years since the app's launch. The growth outlook is supported both by the organic acceleration in downloads and by the new features that iMed will integrate by the end of 2026, giving users more reasons to create an account and use the app in their daily lives.

At the same time, the Group continues to develop the Longevity 100+ program, one of the most ambitious preventive medicine projects in the region. The next phase of the program will expand research beyond data collected in clinics and laboratories to include health information monitored in everyday life. The research will aim to identify conditions and indicators for which the association between genetic predisposition and clinical and paraclinical findings is most pronounced. At the same time, data collected via wearable devices will enable the exploration of associations between polygenic scores and digital biomarkers—such as resting heart rate and heart rate variability—as well as indicators of physical activity and sleep.

Following the large-scale expansion of genetic testing and the introduction, for the first time, of microbiome testing performed entirely in its own laboratories in Romania, MedLife now aims to develop pharmacogenetics services in the near future—a new phase in personalized medicine that will allow treatments to be tailored to each patient's genetic profile and specific characteristics.

MedLife Prepares for the Next Phase of Development: National Consolidation and Regional Expansion

Looking ahead to the next stage of development, MedLife intends to continue strengthening its position locally through investments in technology and medical infrastructure, as well as through selective acquisitions, while simultaneously exploring opportunities for expansion through acquisitions in Central and Southeastern European markets.

In this context, the Group has announced that it is exploring ways to diversify its financing instruments to provide the flexibility needed to support its growth plans. Among the options under consideration is a potential capital increase through the issuance of new shares, intended to finance organic growth projects, investments in technology, and market consolidation opportunities.

At the same time, MedLife aims to establish, in partnership with a leading international financial institution, a regional investment platform focused on health, beauty, and wellness, with a 3- to 5-year implementation timeline. The initiative could facilitate access to capital and additional expertise, supporting gradual expansion into Central and Eastern Europe, with a priority on the Balkan region. This expansion could take place through acquisitions, greenfield investments, and partnerships, depending on the opportunities identified and the Group's profitability criteria.

"*Over nearly three decades, we have built one of the most comprehensive healthcare ecosystems in the region through organic growth, acquisitions, and consistent investments in technology and medical expertise. We believe that the experience we have gained over this time provides us with a solid foundation to explore other products and services in Romania as well as, gradually, new markets, and to scale our development model regionally. We aim to have the flexibility needed to capitalize on opportunities that arise, both in Romania and beyond its borders, while maintaining financial discipline and a focus on return on investment. "Our ambition is to continue developing a regional healthcare platform and to create unique digital models for preventive care and wellness, leveraging Romanian expertise and capital*," **added Mihai Marcu, CEO and Chairman of the Board of Directors of the MedLife Group.**

***

About the MedLife Group

MedLife was founded nearly three decades ago, has grown steadily, and has become the largest provider of private healthcare services in Romania. The Romanian entrepreneurs who founded this company invested and dedicated themselves to bringing about change in the Romanian healthcare system; they believed in innovation and dared to aim high in order to offer Romanian patients quality, professionalism, care, and respect for their needs.

The company operates the most extensive network of clinics, one of the largest networks of medical laboratories, general and specialized hospitals, and has the largest corporate client base for preventive health care packages in the country. It is also, in terms of sales, one of the largest private healthcare providers in Central and Eastern Europe.

The MedLife Group has a proven track record of success in both organic growth and growth through acquisitions. Its strong and experienced management team has been able to create and manage these growth opportunities, gaining valuable knowledge and experience that enable it to chart the best course for continued successful expansion.

As a Romanian company with a long tradition, MedLife chose to list on the Romanian Stock Exchange, serving as a model for listings on the local capital market. It has broadened horizons, and through its corporate governance practices, it has inspired other local companies to follow this path and contribute to the development of Romanian capital and the economy. The shares issued by MedLife SA are admitted to trading on the regulated spot market administered by the Bucharest Stock Exchange, Premium Category, under the ticker symbol M.

During the pandemic, MedLife played a vital role in society and established itself as a leader in pandemic monitoring through its active involvement in research.

The company continues to invest in projects that benefit the local community, as well as in technology and infrastructure. It creates jobs and fosters an ecosystem that contributes to the development and maintenance of a healthy Romania.